• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

JPM 2022: Bluebird bio hopes for clear skies ahead as it gears up for trio of gene therapy...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jan 13, 2022 at 10:52: PM
via Bluebird is readying the commercial nest ahead of a May decision on its beta thalassemia gene therapy beti-cel, also known as Zynteglo. Those preparations will be "crucial" to unlocking the blockbuster potential of lovo-cel in sickle cell disease (SCD) next year, should that drug pass muster at the FDA, bluebird CEO Andrew Obenshain said Wednesday at the 2022 J.P. Morgan Healthcare Conference.

article source
 




Top Bottom
Back
Quote